Edelman Public Relations Worldwide
Lobbying costs:
WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.
WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.
900,000€ - 999,999€
Lobbyists declared: 7 FTE (18)
WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.
Lobbyists with EP accreditation: 16
Meetings with European Commission: 18
Lobbying costs over the years:
Edelman Public Relations Worldwide
Registration on EU Transparency Register
Website
Goals / Remit
Edelman is the world’s leading independent public relations firm with over 4,800 employees in 67 offices worldwide. Our public affairs practice has more than 200 professionals in key political capitals, including Brussels, Beijing, Berlin, London, Paris and Washington, D.C.
Edelman Brussels benefits from a multinational and multilingual staff with experience in European Union institutions, national governments, business, NGOs and the media.
We offer public affairs and strategic communications advice and implementation, as well as a link to our worldwide network, in a wide range of sectors including energy and climate change, environment, transport, ICT, agriculture, food, healthcare and financial services.
Issues
• Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the European Regional Development Fund and on the Cohesion Fund • Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on Horizon Europe- The Framework for Research and Innovation • REGULATION (EC) No 1008/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 24 September 2008 on common rules for the operation of air services in the Community • 2018/0082(COD): Unfair trading practices in business-to-business relationships in the food supply chain • 2018/0090(COD): EU consumer protection rules: enforcement and modernisation • DIRECTIVE 2011/24/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 9 March 2011 on the application of patients’ rights in cross-border healthcare • REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products • Evaluation of the legislation on medicines for children and rare diseases (medicines for special populations)
Address
Avenue Marnix, 28
Brussels 1000,
Belgium
Tel: 32 25480267